Gene Polymorphisms in Tacrolimus Drug Interactions (DDI-TAC)

This study has been completed.
Sponsor:
Collaborator:
Fund for Scientific Research, Flanders, Belgium
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00620841
First received: February 13, 2008
Last updated: February 21, 2008
Last verified: January 2008
  Purpose

A retrospective analysis of the influence of gene polymorphisms on drug interactions between calcineurin-inhibitors and concomitant drugs in renal transplant patients.


Condition Intervention
Renal Transplantation
Other: genotyping

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Gene Polymorphisms in Tacrolimus Drug Interactions in Renal Transplant Patients

Resource links provided by NLM:


Further study details as provided by Katholieke Universiteit Leuven:

Primary Outcome Measures:
  • Tacrolimus exposure parameters [ Time Frame: weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tacrolimus daily dosing [ Time Frame: weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

DNA samples


Enrollment: 40
Study Start Date: May 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
A
Patients treated with tacrolimus and experiencing a drug interaction
Other: genotyping
Restriction fragment lenght polymorphisms

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Renal transplant recipients treated with a calcineurin-inhibitor

Criteria

Inclusion Criteria:

  • Treatment with calcineurin-inhibitor
  • Renal transplantation

Exclusion Criteria:

  • Drug, alcohol addiction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620841

Locations
Belgium
University Hospitals Leuven
Leuven, Brabant, Belgium, B-3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Fund for Scientific Research, Flanders, Belgium
Investigators
Principal Investigator: Dirk R Kuypers, MD, PhD Universitaire Ziekenhuizen Leuven
  More Information

No publications provided

Responsible Party: Catholic University Leuven, University Hospitals, University Hospital Gasthuisberg
ClinicalTrials.gov Identifier: NCT00620841     History of Changes
Other Study ID Numbers: DDI-001
Study First Received: February 13, 2008
Last Updated: February 21, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by Katholieke Universiteit Leuven:
Tacrolimus
Renal Transplantation
genetic polymorphisms
Drug drug interactions

Additional relevant MeSH terms:
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 29, 2014